Belvedere Trading
TNGX icon

Belvedere Trading’s Tango Therapeutics TNGX Stock Holding History

Belvedere Trading’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,300
Closed -$27.7K – 1083
2025
Q3 		$27.7K Buy
3,300
+600
+22% +$4.06K ﹤0.01% 740
2025
Q2 		$13.8K Buy
+2,700
New +$6.68K ﹤0.01% 699

Other funds holding TNGX

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Belvedere Trading's TNGX Position: Q4 2025 in Review

Belvedere Trading sold out of Tango Therapeutics (TNGX) in Q4 2025, closing a stake of 10,845 shares — an estimated $91.1K sold.

Belvedere Trading first reported a position in TNGX in Q2 2025 and held it in 2 quarters. The position peaked at $91.1K in Q3 2025. 170 funds tracked by Wall St. Rank hold TNGX as of Q4 2025.

  • Belvedere Trading reported no remaining Tango Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Belvedere Trading sold 10,845 Tango Therapeutics shares in Q4 2025, an estimated $91.1K.
  • Belvedere Trading first reported a position in Tango Therapeutics in Q2 2025 and held it in 2 quarters.
  • Belvedere Trading's Tango Therapeutics position peaked at $91.1K in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2025.

Based on Belvedere Trading's 13F filing for Q4 2025, filed 10 Feb 2026.